ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Angiotensin-(1-7) decreases inflammation and lung damage caused by betacoronavirus infection in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Review
- Estrogens as a Possible Therapeutic Strategy for the Management of Neuroinflammation and Neuroprotection in COVID-19.Current neuropharmacology · 2023Article
- Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.Medicinal research reviews · 2022Review
- Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.Biomedicines · 2022Article
- Article
- Genetic and non-genetic risk factors associated with atrial fibrillation.Life sciences · 2022Review
- The COVID-19-diabetes mellitus molecular tetrahedron.Molecular biology reports · 2022Review
- Patients with severe COVID-19 have reduced circulating levels of angiotensin-(1-7): A cohort study.Health science reports · 2022Article
- Molecular and cellular mechanisms involved in tissue-specific metabolic modulation by SARS-CoV-2.Frontiers in microbiology · 2022Review
- Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2.Computational and structural biotechnology journal · 2022Article
- Review
- A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.Emerging microbes & infections · 2021Review
- The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.Veterinary world · 2021Review
- Implications of the COVID-19 Pandemic for Cardiovascular Disease and Risk-Factor Management.The Canadian journal of cardiology · 2021Review
- Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.Molecules (Basel, Switzerland) · 2021Review
- Renin-angiotensin system at the interface of COVID-19 infection.European journal of pharmacology · 2021Review
- Alamandine: Potential Protective Effects in SARS-CoV-2 Patients.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2021Review
- Commonalities Between COVID-19 and Radiation Injury.Radiation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ACE2 is a receptor of entry of SARS-CoV-2 into the host cells, and its upregulation has been implicated in increasing susceptibility of individuals to this infection. The clinical picture of COVID-19 suggests a role of ACE2 blockade, rather than its overexpression, in causing the pathogenesis. ACE2 blockade results in increased angiotensin II activity with simultaneous hampering of functions of angiotensin-(1-7)/MasR axis. Acute respiratory distress due to interstitial pulmonary fibrosis, cardiomyopathy and shock reported in COVID-19 patients can be explained by imbalanced angiotensin II and angiotensin-(1-7) activities. Failure of angiotensin II type 1 receptor blockers to control the severity of SARS-CoV-2 infections indicates the importance of simultaneous induction of angiotensin-(1-7)/MasR axis for correcting pathological conditions in COVID-19 through its anti-fibrotic, anti-inflammatory, vasodilatory, and cardioprotective roles. MasR agonists have also shown organ protective effects in a number of animal studies. Unfortunately, these agonists have not been tested in clinical studies. Their evaluation in seriously ill COVID-19 patients is urgently warranted to reduce mortality due to infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.